Bruker Corporation BRKR
NASDAQ · United States · Health Technology
$64.75+0.24 (+0.37%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SINGAPORE, September 28, 2026--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF d
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Bruker Corporation previously announced a multi-system order worth more than US$6.00 million from the University of California, Berkeley to equip the Pines Magnetic Resonance Center with next-generation high-field NMR instrumentation, including an AV NEO-X 800 MHz spectrometer with a cryogenically cooled MAS CryoProbe and multiple supporting systems, scheduled for delivery in 2027. This large academic investment highlights how Bruker’s advanced NMR platforms are being embedded in...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.